Jun 4, 2026 7:30 am EDT Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Jun 2, 2026 7:00 am EDT Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
May 12, 2026 4:05 pm EDT Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
May 1, 2026 12:15 pm EDT Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Apr 21, 2026 7:00 am EDT Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
Mar 24, 2026 7:00 am EDT Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
Feb 12, 2026 4:05 pm EST Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
Feb 4, 2026 7:00 am EST Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
